focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

10 Jul 2020 11:23

RNS Number : 6912S
Omega Diagnostics Group PLC
10 July 2020
 

 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Result of General Meeting

 

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces, further to the announcement of 19 June 2020, the passing of the Resolutions at the General Meeting held earlier today. The Placing, Subscription and Open Offer remain conditional on Admission of the New Ordinary Shares to AIM which is expected to take place at 8.00 a.m. Monday 13 July 2020.

 

Voting details

The vote for Resolution 1 was carried out as a poll on the basis of proxies received and the votes of those present (45,789,393 for and 167,575 against, with 54,677 votes withheld), and on the basis of such poll it was resolved that Resolution 1 as contained in the Notice be passed as an Ordinary Resolution.

 

The vote for Resolution 2 was carried out as a poll on the basis of proxies received and the votes of those present (45,789,393 for and 167,575 against, with 54,677 votes withheld), and on the basis of such poll it was resolved that Resolution 2 as contained in the Notice be passed as a Special Resolution.

 

Total Voting Rights

With effect from Admission the Company will have 178,153,110 Ordinary Shares in issue, with no shares held in treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.

 

Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Company's circular dated 19 June 2020.

 

 

 

For further information, please contact:

 

Omega Diagnostics Group PLC 

Tel: 01259 763 030

Colin King, Chief Executive 

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director

finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash / Hannah Boros / Teddy Whiley (Corporate Finance)

Camille Gochez (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

 

Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):

1.

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Colin King

2.

Reason for notification

b)

Position / status

CEO

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

 

ordinary shares of 4p each

 

 

GB00B1VCP282

b)

Nature of the transaction

Acquisition of shares pursuant to the Placing

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.40

50,000

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

13 July 2020

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1.

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Kieron Harbinson

2.

Reason for notification

b)

Position / status

CFO

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

 

ordinary shares of 4p each

 

 

GB00B1VCP282

b)

Nature of the transaction

Acquisition of shares pursuant to the Subscription and Open Offer

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.40

35,914

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

13 July 2020

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1.

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Jag Grewal

2.

Reason for notification

b)

Position / status

Commercial Director

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

 

ordinary shares of 4p each

 

 

GB00B1VCP282

b)

Nature of the transaction

Acquisition of shares pursuant to the Placing

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.40

22,500

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

13 July 2020

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1.

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Jeremy Millard

2.

Reason for notification

b)

Position / status

Non-Executive Director

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

 

ordinary shares of 4p each

 

 

GB00B1VCP282

b)

Nature of the transaction

Acquisition of shares pursuant to the Subscription

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.40

25,000

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

13 July 2020

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROMBBLFFBDLLBBF
Date   Source Headline
4th Jan 20224:36 pmRNSPrice Monitoring Extension
14th Dec 20217:00 amRNSConfirmation of detection of Omicron variant
10th Dec 20212:06 pmRNSSecond Price Monitoring Extn
10th Dec 20212:01 pmRNSPrice Monitoring Extension
10th Dec 20219:30 amRNSDHSC contract update
1st Dec 20214:40 pmRNSSecond Price Monitoring Extn
1st Dec 20214:35 pmRNSPrice Monitoring Extension
1st Dec 20212:05 pmRNSSecond Price Monitoring Extn
1st Dec 20212:00 pmRNSPrice Monitoring Extension
26th Nov 20212:06 pmRNSSecond Price Monitoring Extn
26th Nov 20212:00 pmRNSPrice Monitoring Extension
25th Nov 20219:06 amRNSSecond Price Monitoring Extn
25th Nov 20219:00 amRNSPrice Monitoring Extension
25th Nov 20217:00 amRNSHalf-year Report
5th Nov 20217:00 amRNSNotice of Results and Investor Presentation
3rd Nov 20217:00 amRNSUpdate on CTDA Regulations
1st Nov 20213:28 pmRNSExercise of Options and Total Voting Rights
1st Nov 20217:00 amRNSPartnership with DAM Health and initial LFT order
19th Oct 202112:00 pmRNSExercise of Options and Total Voting Rights
15th Sep 20213:26 pmRNSResult of AGM
15th Sep 20217:00 amRNSAGM Statement
30th Jul 202112:35 pmRNSPosting of Annual Report & Accounts &Notice of AGM
27th Jul 20217:00 amRNSAbC-19 monitors vaccine response to variants
13th Jul 20217:01 amRNSFinal Results
13th Jul 20217:00 amRNSDirectorate Change
9th Jul 20219:08 amRNSAbC-19 rapid antibody test performance evaluation
2nd Jul 20217:00 amRNSFDA submission for Emergency Use Authorization
16th Jun 20217:00 amRNSNotice of Results
15th Jun 202110:49 amRNSStatement re. Media Comment
10th Jun 20212:05 pmRNSSecond Price Monitoring Extn
10th Jun 20212:00 pmRNSPrice Monitoring Extension
8th Jun 20217:00 amRNSRegulatory progress for VISITECT® COVID-19 test
7th Jun 20217:00 amRNSProgress update
1st Jun 20217:00 amRNSPositive data for COVID-19 antigen test
6th May 20214:41 pmRNSSecond Price Monitoring Extn
6th May 20214:35 pmRNSPrice Monitoring Extension
5th May 20217:00 amRNSPositive data for Mologic COVID-19 antigen test
30th Apr 20211:30 pmRNSExercise of Options and Total Voting Rights
30th Apr 20217:00 amRNSLaunch of VISITECT® COVID-19 Antigen & Update
23rd Apr 202110:30 amRNSDirector/PDMR Shareholding and Total Voting Rights
19th Apr 20217:00 amRNSDirector/PDMR Shareholding
31st Mar 202112:31 pmRNSDirector/PDMR Shareholding and Total Voting Rights
26th Mar 20215:36 pmRNSExercise of Options and Total Voting Rights
26th Mar 20214:40 pmRNSSecond Price Monitoring Extn
26th Mar 20214:35 pmRNSPrice Monitoring Extension
22nd Mar 20217:00 amRNSCE-Mark: Mologic COVID19 lateral flow antigen test
19th Mar 20211:15 pmRNSExercise of Options and Total Voting Rights
15th Mar 20215:28 pmRNSStatement re. Government press release
15th Mar 20217:00 amRNSUK Public Sector Contract disclosure
8th Mar 20217:00 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.